Quantum BioPharma receives FDA clearance for Lucid-MS Phase 2 trials

Quantum BioPharma has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its lead multiple sclerosis (MS) drug candidate, Lucid-MS. This approval allows the company to proceed with Phase 2 clinical testing.

Unlike many existing MS therapies that focus on suppressing or modifying the immune response, Lucid-MS is designed to address demyelination directly. The drug aims to inhibit the enzyme peptidyl arginine deiminase 2 (PAD2), which is associated with myelin breakdown. The company previously completed Phase 1 trials, which indicated a favorable safety profile.

Multiple sclerosis is a chronic disease of the central nervous system that affects approximately 2.9 million people globally. In the United States, recent research suggests nearly one million people are living with the condition. Current approved therapies often fail to reverse the neurodegeneration that leads to long-term disability, highlighting the potential need for new approaches like Lucid-MS.